Abstract
Female rats bearing N-nitrosomethylurea-induced mammary carcinomas were treated with pergolide mesylate to suppress serum prolactin. The drug was given alone, or with somatostatin, 20 micrograms/hr delivered by osmotic minipump for 7 days to suppress serum growth hormone. Tumour regressions did not occur with pergolide alone, but did so promptly in all of 5 rats when growth hormone levels were also suppressed by somatostatin. A potent long-acting agonistic analogue of somatostatin, L362,823 produced similar tumour regressions at a dose of 5 micrograms/hr when given with pergolide, but was ineffective alone. This dose completely prevented the episodic release of pituitary growth hormone.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Drug Therapy, Combination
-
Ergolines / administration & dosage
-
Female
-
Growth Hormone / blood*
-
Hypophysectomy, Chemical
-
Mammary Neoplasms, Experimental / blood
-
Mammary Neoplasms, Experimental / drug therapy*
-
Mammary Neoplasms, Experimental / pathology
-
Methylnitrosourea
-
Pergolide
-
Prolactin / blood*
-
Rats
-
Rats, Inbred Strains
-
Somatostatin / administration & dosage
-
Somatostatin / analogs & derivatives
Substances
-
Ergolines
-
Pergolide
-
Somatostatin
-
Methylnitrosourea
-
cyclo(aminoheptanoic acid-cyclo(cysteinyl-phenylalanyl-D-tryptophyl-lysyl-threonyl-cysteinyl))
-
Prolactin
-
Growth Hormone